Article Text

Download PDFPDF
ESRA19-0365 Vectors study: primary and secondary results assessing pain relief and functional outcomes using spinal cord stimulation (SCS) with high dose (HD) stimulation parameters
  1. J Hatheway1,
  2. V Mangal2,
  3. F Michael3,
  4. S Binit4,
  5. V Michael5,
  6. M Kelly6,
  7. K Stromberg6 and
  8. K Hendrickson6
  1. 1Northwest Pain Care, Pain Management, Spokane, USA
  2. 2Advanced Spine and Pain, Pain Management, Stafford, USA
  3. 3Center for Interventional Pain and Spine, Pain Management, Wilmington, USA
  4. 4Carolinas Pain Center, Pain Management, Huntersville, USA
  5. 5Pain Consultants of San Diego, Pain Management, San Diego, USA
  6. 6Medtronic, Pain-Stim, Minneapolis, USA


Background and aims SCS delivers energy to the spinal cord with the goal of symptom relief from chronic intractable pain. Research suggests targeting stimulation at the midline of the spinal cord, starting at the T9-T10 disc space for back pain.1 2 Recently, the effects of high energy parameters at this target have been explored, particularly stimulation at 1000 Hz.3 4

The Vectors study evaluates whether there is significant improvement in pain starting with HD stimulation at 1000 Hz when leads span the T9-T10 disc space.

Methods Post-market, single-arm study evaluating the efficacy of SCS (IntellisTM implantable neurostimulator) starting with HD stimulation, targeting the T9-T10 disc space following paresthesia mapping (EvolveSM workflow). Subjects with chronic intractable low-back and leg pain (VAS ≥50 mm) were enrolled.

Primary endpoint Change in overall pain (VAS) at 3-month visit compared to baseline.

Results 98 subjects completed the 3-month visit. Overall pain decreased 45.8 mm on the VAS. 87% of subjects had > 50% improvement in at least one pain domain (overall, back or leg). Benefits were observed in the ODI; 65.3% improved by at least 1 category and EQ-5D; 75.5% of subjects improved on at least one dimension and no worse in other dimensions. 70% of subjects achieved a personal activity goal and 81.6% reported therapy satisfaction.

Abstract ESRA19-0365 Figure 1

Responder rates and 95% confidence intervalsSubjects were defined as responders if they had at least a 50% improvement in their pain, as assessed by the VAS, from Baseline to the 3-Month Visit. Responders rates for Overall, Low-Back, and Leg are presented.

Abstract ESRA19-0365 Figure 2

Change in painNinety-eight subjects implented with an Intellis™ completed their 3-Month Visit. Change in VAS for Overall, Back, and Leg are presented.

Abstract ESRA19-0365 Figure 3

ODI categories at baseline and 3 monthsPrecent of subjects in the Severe/Crippled/Bed-bound disability categories decreased from 82.6% at Baseline to 34.7% at 3 Months.

Abstract ESRA19-0365 Figure 4

Change in EQ-5D at 3 monthsOf the 98 subjects who completed a 3-Month Visit, 74(75.5%) improved in at least 1 dimension an no worse in other dimension. EQ VAS improved from Basline (56.5) to 3months (70.3)

Abstract ESRA19-0365 Figure 5

Percentage of subjects who achieved activity goal by visit70% of subjects had achieved an activity goal set at their Basline visit by the 3-Month Visit.

Abstract ESRA19-0365 Figure 6

Subject satisfication with therapyEight subject (81.61%) were satisfied with their therapy at the 3-Month visit

Conclusions Vectors PM provides evidence for SCS starting with HD stimulation (the EvolveSM workflow). a statistically significant reduction in pain was achieved at 3-months follow-up. Benefits were also observed in quality of life and function. Subjects are followed through 12-months post-implant to assess sustainability of outcomes.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.